Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hetero Biopharma
Hyderabad, Telangana, Indiaheterobiopharma.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Hetero Biopharma has commercialized at least six biosimilar products including darbepoetin alfa ("Derise"), rituximab ("Rilast"), bevacizumab ("Bevaas"), adalimumab ("Pamera"), trastuzumab ("Sezuma") and filgrastim. The company claims to be among the first globally to launch certain biosimilars. Additional programs are in various stages of clinical development or regulatory review.
- Therapeutic areas
- HematologyOncologyNephrologyImmunologyRheumatology
- Modalities
- Monoclonal antibodyRecombinant proteinVaccineCell therapyGene therapySmall moleculeAntibody-drug conjugate
- Industry
- Biotech
02
Partnerships
Strategic partnerships with multinational pharmaceutical companies and global procurement bodies for commercialization/distribution of critical drugs.
Beyond the preview
Go deeper on Hetero Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hetero Biopharma.